A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses

PURPOSE: Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, has shown activity in advanced thyroid cancer in a Phase II study. We report updated overall survival and pharmacokinetic/pharmacodynamic (PK/PD) analyses from the study. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, E. E. W., Tortorici, M., Kim, S., Ingrosso, A., Pithavala, Y. K., Bycott, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236619/
https://www.ncbi.nlm.nih.gov/pubmed/25315258
http://dx.doi.org/10.1007/s00280-014-2604-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236619/
https://www.ncbi.nlm.nih.gov/pubmed/25315258
http://dx.doi.org/10.1007/s00280-014-2604-8

Ejemplares similares